MX2019015007A - Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. - Google Patents

Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.

Info

Publication number
MX2019015007A
MX2019015007A MX2019015007A MX2019015007A MX2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A MX 2019015007 A MX2019015007 A MX 2019015007A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
staphylococcus aureus
lukb
luka
derived polypeptides
Prior art date
Application number
MX2019015007A
Other languages
English (en)
Inventor
Mohammad Javad Aman
Thomas Kort
Nils Williston
Shweta Kailasan
Hatice Karauzum
Rajan P Adhikari
Original Assignee
Integrated Biotherapeutic Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Biotherapeutic Vaccines Inc filed Critical Integrated Biotherapeutic Vaccines Inc
Publication of MX2019015007A publication Critical patent/MX2019015007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona composiciones inmunogénicas útiles en la prevención y el tratamiento de infecciones por Staphylococcus aureus. En particular, la descripción proporciona métodos para inducir una respuesta inmunitaria contra un S. aureus que expresa LukAB, métodos para prevenir o tratar infecciones por S. aureus y una composición para prevenir o tratar infecciones por S. aureus.
MX2019015007A 2017-06-13 2018-06-13 Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. MX2019015007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762518641P 2017-06-13 2017-06-13
PCT/US2018/037376 WO2018232014A1 (en) 2017-06-13 2018-06-13 Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides

Publications (1)

Publication Number Publication Date
MX2019015007A true MX2019015007A (es) 2020-08-06

Family

ID=64660858

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015007A MX2019015007A (es) 2017-06-13 2018-06-13 Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.

Country Status (7)

Country Link
US (1) US11421021B2 (es)
EP (1) EP3638286A4 (es)
CN (1) CN110913883A (es)
AU (1) AU2018285857B2 (es)
CA (1) CA3066450A1 (es)
MX (1) MX2019015007A (es)
WO (1) WO2018232014A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3155424A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
CA3195895A1 (en) * 2020-09-28 2022-03-31 Janssen Pharmaceuticals, Inc. Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions
CN116078360B (zh) * 2023-03-07 2023-06-23 佛山市博新生物科技有限公司 一种清除白细胞及致病抗体的吸附纤维膜及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20050008633A1 (en) 2003-05-19 2005-01-13 Advanced Inhalation Research Inc. Chemical and physical modulators of bioavailability of inhaled compositions
BR112012029521A2 (pt) * 2010-05-05 2018-03-06 New York University leucocidinas do staphylococcus aureus, composições terapêuticas, e aplicações das mesmas.
PL2668208T3 (pl) 2012-04-17 2015-12-31 Arsanis Biosciences Gmbh Krzyżowo reaktywne przeciwciało rozpoznające Staphylococcus aureus
CA2871152A1 (en) * 2012-05-02 2013-11-07 New York University Methods of treating and preventing staphylococcus aureus infections and associated conditions
JP6560195B2 (ja) * 2013-05-21 2019-08-14 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 黄色ブドウ球菌のＬｕｋＧＨ（ＬｕｋＡＢ）毒素を中和する、非常に強力な抗体の生成
CA2931327A1 (en) 2013-12-19 2015-06-25 Arsanis Biosciences Gmbh Antibodies directed against the lukgh (lukab) toxin of staphylococcus aureus and antibody sequences
JP2018517708A (ja) * 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法

Also Published As

Publication number Publication date
CA3066450A1 (en) 2018-12-20
US20200317759A1 (en) 2020-10-08
US11421021B2 (en) 2022-08-23
EP3638286A4 (en) 2021-03-10
CN110913883A (zh) 2020-03-24
AU2018285857A1 (en) 2020-01-02
WO2018232014A1 (en) 2018-12-20
EP3638286A1 (en) 2020-04-22
AU2018285857B2 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
MX2023003461A (es) Tratamiento de infeccion por clostridium difficile.
MX2023013140A (es) Vacunas contra el virus de la hepatitis b.
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
WO2015181356A8 (en) Vaccine composition against streptococcus suis infection
WO2016179440A3 (en) Antimicrobial therapy
MX2019015007A (es) Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb.
WO2016109689A3 (en) Derivatives and methods of treating hepatitis b infections
WO2016108045A3 (en) Antimicrobial compounds, compositions and methods
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
WO2015110969A3 (en) Nitrogen containing compounds and their use as antibacterial agents
PH12016502003A1 (en) Novel bacteriophage and composition containing same
WO2016004513A8 (en) Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods
MX2021002719A (es) Cannabinoides para el tratamiento de infecciones grampositivas incluidas cepas bacterianas resistentes a antibióticos.
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2018001512A (es) Composiciones antimicrobianas que comprenden mupirocina y neomicina.
MX2017014080A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
PH12019502915A1 (en) Immunogenic compositions
MY183483A (en) Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
WO2016072854A3 (en) Pantothenamide analogues
AU2018272839A8 (en) Fractionated antimicrobial compositions and use thereof